Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

Custom ADA (Anti-Drug Antibody) Generation Services

Open
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

6138, MD, USA

Set-Aside

NONE

Documents

This scope was carved out of 75N98027R00020.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Due in 14 days

Read the full solicitation package

This scope is part of a larger contract. Its documents live on the prime.

  • 1 document on the prime contractFrom Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics
Read the prime's documents

Ask CLEATUS

I've read this contract. Ask me anything.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Nida
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Performs generation of high-affinity, specific anti-drug antibodies (ADAs) and neutralizing antibodies (nAbs) for prime contractors on NIH/NCATS biotechnology projects. Generates polyclonal and monoclonal ADAs, including antibodies against vector capsids and gene-of-interest protein products. Utilizes animal facilities, hybridoma technology, or recombinant platforms. Requires compliance with vertebrate animal welfare, GLP, and GCP. Delivers unpurified or semi-purified antibody candidates.

Similar Contracts

Same NAICS industry code

NAICS: 541715
New
SBIR / STTR
Ground-Based Affordable Mass (G-BAM)
Solicitation # ARM26BX04-DV010
The Ground-Based Affordable Mass (G-BAM) solicitation, issued by the U.S. Army under the U.S. Department of Defense, is a total small business set-aside opportunity utilizing a direct-to-Phase II SBIR structure. The program is designed as a three-phased effort, where Phase I typically lasts six to twelve months and Phase II generally spans 24 months. Proposals are submitted via the DSIP portal and must be organized into seven specific volumes, including technical, cost, and commercialization reports. Technical proposals must adhere to strict formatting guidelines, including a single PDF format, one-inch margins, and a minimum 10-point font, with a risk of rejection if page limits are exceeded. Award selections are based on the overall technical value and cost, with a primary focus on technical capability, innovation, and the qualifications of key personnel. Evaluation factors are prioritized by the soundness of the technical approach, the ability of the team to perform R&D and commercialize results, and the overall commercial potential for government or private sector application. To be eligible, proposing entities must be registered in the System for Award Management (SAM) and the SBA Company Registry. Additionally, contractors must comply with stringent security and legal requirements, including the Cybersecurity Maturity Model Certification (CMMC) program, Foreign Risk Evaluation (FRE), and the disclosure of any organizational conflicts of interest.
U.S. Army

POSTED

about 11 hours ago

DEADLINE

in 14 days
View Details
NAICS: 541715
New
Federal
UNITED STATES ARMY RESEARCH INSTITUTE FOR THE BEHAVIORAL AND SOCIAL SCIENCES (ARI) BROAD AGENCY ANNOUNCEMENT FOR BASIC, APPLIED, AND ADVANCED SCIENTIFIC RESEARCH
Solicitation # W911NF-23-S-0010
Broad Agency Announcement W911NF-23-S-0010 is a multi-year solicitation issued by the United States Army Research Institute for the Behavioral and Social Sciences (ARI) to acquire basic, applied, and advanced scientific research. Valid from May 1, 2023, to April 30, 2028, the BAA focuses on enhancing Army readiness and performance through the behavioral and social sciences. Key research areas include holistic personnel assessment, job classification and assignment, leadership development for organizational and strategic leaders, team composition and effectiveness in future operational environments, and the assessment of technological fluency. The acquisition process typically follows a three-step sequence: initial contact with an ARI Technical Point of Contact, submission of a white paper (limited to six pages), and a subsequent full proposal if encouraged. Proposals are evaluated based on scientific and technical merit, potential contribution to the ARI mission, qualifications of key personnel, and cost, with technical merit weighted most heavily. Award instruments may include contracts or grants, with specific project budgets ranging from approximately 320,000 dollars for creative performance research to 1.35 million dollars for career progression studies. Administrative requirements include registration in the System for Award Management and the provision of CAGE codes and Taxpayer Identification Numbers. Proposals must adhere to strict formatting guidelines, including a 23-page limit for core technical sections. Special provisions are in place regarding Organizational Conflicts of Interest, particularly for entities with existing Intergovernmental Personnel Act agreements, and strict prohibitions against including classified information in white papers.
W6QK Acc-Apg Durham

POSTED

about 12 hours ago

DEADLINE

in over 1 year
View Details
NAICS: 541715
New
Federal
Notice of Intent (NOI) to Sole Source proprietary prodrug MP201 to ISB for testing Acute Stress Reactions (ASRs)
Solicitation # HT9426-27-NOI-049825
The Defense Health Agency, on behalf of the Walter Reed Army Institute of Research, has issued a Notice of Intent to sole source the procurement of the proprietary prodrug MP201 to the Integrative Systems Biology (ISB) Branch. The primary objective is to support the testing of Acute Stress Reactions (ASRs). The scope of work requires the contractor to supply two freshly made batches of MP201 synthesized for oral administration in mice, with target dosages ranging approximately from 8 to 80 mg/kg body weight. In addition to the physical product, the contractor must provide quality control documentation, dosage background information, and technical support to assist the ISB research team in preparing related reports and manuscripts. This action is identified by solicitation number HT9426-27-NOI-049825 and is categorized under NAICS code 541715. As this is a Notice of Intent and not a request for competitive proposals, no formal solicitation document or pricing data is currently available. Interested parties must submit capability statements in writing via PDF, MS Word, or Excel to Herbert Keen or Lance Nowell by 2:00 p.m. Eastern Time on December 31, 2026. All submissions must be unclassified, as the agency has explicitly stated that classified material should not be submitted.
Defense Health Agency

POSTED

about 12 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541715
New
Federal
AUTOIMMUNE DISEASES STATISTICAL & CLINICAL COORDINATING CENTER (AD-SCCC)
Solicitation # 75N93026R00009
The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH) is seeking to extend the contract for the Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC). This project provides essential support for the design, development, execution, and analysis of clinical research focused on autoimmune diseases, mucosal immunology, and primary immune deficiencies. The scope of work includes supporting the Autoimmunity Centers of Excellence and Immune Tolerance Network (ACE) and investigator-initiated clinical trials (IICT). Key responsibilities encompass statistical design and analysis, protocol development, data management, clinical safety and pharmacovigilance support, and the management of biological specimen repositories and collaboration portals. The NIAID intends to negotiate a sole source modification with Rho Federal Systems Division, Inc. under FAR Part 6.302-1 and HHSAR Part 306.302-1 to avoid significant disruptions to critical services and ensure participant safety and data integrity. The proposed 18-month extension is structured as two discrete option periods: a 12-month period from February 1, 2027, through January 31, 2028, and a 6-month period through July 31, 2028. This extension maintains the existing term type/level of effort contract structure and scope to ensure continuity of operations while the agency completes a separate competition process.
National Institutes Of Health Niaid

POSTED

about 12 hours ago

DEADLINE

in 15 days
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health Nida

Same awarding agency

NAICS: 325411
New
Federal
Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics
Solicitation # 75N98027R00020
The National Center for Advancing Translational Sciences within the National Institutes of Health has issued a Sources Sought notice for an IDIQ contract focused on reagent generation for bioanalytical method development on biologics therapeutics. The primary objective is to identify qualified sources capable of generating and delivering high-affinity, specific anti-drug antibodies, including neutralizing antibodies and antibodies against carriers or gene-of-interest protein products. These reagents will support the quantification of novel biologic drugs in biological matrices such as plasma, serum, and tissue homogenates. The anticipated scope includes the production of polyclonal and monoclonal antibodies, specificity characterization, and the delivery of purified antibodies at an estimated scale of 10 to 50 mg per reagent. The required performance standards are rigorous, demanding adherence to US FDA current Good Manufacturing Practice, Good Laboratory Practice, and Good Clinical Practice, as well as ICH and ISO regulations. Contractors must maintain a comprehensive Quality Management Plan and an independent Quality Assurance Unit to ensure all products meet strict quality requirements. Additional requirements include the development of standard operating procedures for packaging and shipping, the maintenance of secure facilities with restricted access, and the implementation of contingency plans for catastrophic events. The anticipated period of performance for this effort is ten years. Interested respondents must be registered in the System for Award Management and provide a capability statement under NAICS code 325411 by November 30, 2026.
Medicinal and Botanical Manufacturing

POSTED

about 12 hours ago

DEADLINE

in 14 days
View Details
NAICS: 541715
Federal
Synthesis and Distribution of Drugs of Abuse and Related Compounds
Solicitation # 75N98027R00006OT
The National Institute on Drug Abuse (NIDA) is issuing a Sources Sought Notice to identify qualified business organizations capable of supporting the synthesis and distribution of drugs of abuse and related compounds. This is not a solicitation for proposals, but a market research effort to determine the availability of technically capable commercial or non-commercial sources and to identify the appropriate acquisition method. The scope of work involves producing, acquiring, and maintaining an inventory of labeled and unlabeled chemical substances, ensuring purity levels of at least 95 percent, and managing the secure storage and shipment of these compounds to research investigators. Interested vendors must demonstrate the ability to handle large quantities of DEA controlled and uncontrolled substances, including peptides, narcotics, and stimulants, some of which require refrigeration. A mandatory requirement for any capable vendor is the possession of a DEA Research Registration for Schedules II through V and the ability to obtain registration for Schedule I substances. Organizations must submit a capability statement of no more than ten pages, including their UEI number, business size, and detailed evidence of staff expertise and prior experience, to the designated Contract Specialist by November 20, 2026.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

18 days ago

DEADLINE

in 4 days
View Details
NAICS: 541715
Federal
Synthesis and Distribution of Drugs of Abuse and Related Compounds
Solicitation # 75N98027R00006SB
The National Institute on Drug Abuse (NIDA) is issuing a Small Business Sources Sought Notice to identify qualified small business organizations capable of supporting the synthesis and distribution of drugs of abuse and related compounds. This is a market research effort to determine the availability of technically capable sources and to decide if a small business set-aside is appropriate under NAICS code 541715. The scope of work includes producing, acquiring, and maintaining an inventory of labeled and unlabeled chemical substances, testing for purity, managing the Drug Inventory Supply Control System (DISCS), and ensuring the secure storage and shipment of compounds to research investigators. Interested vendors must demonstrate the ability to store large quantities of DEA-controlled and uncontrolled substances, including peptides, while maintaining a purity level of at least 95 percent. A mandatory requirement for this effort is that vendors possess a DEA Research Registration for Schedules II through V and show the capability to obtain registration for Schedule I substances. Qualified small businesses must submit a capability statement, limited to ten pages, to the designated contract specialist by November 20, 2026. This notice is for information purposes only and does not constitute a solicitation or a commitment to award a contract.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

18 days ago

DEADLINE

in 4 days
View Details
NAICS: 541690
Federal
Modification to Extend Services for Scientific, Operations and Administrative Resources (SOAR) Contract Program
Solicitation # OLAO-SSD-SOAR-NOI
The National Institutes of Health (NIH) intends to negotiate and award non-competitive modifications to extend the Scientific, Operations and Administrative Resources (SOAR) contract program. This program consists of five indefinite-delivery, indefinite-quantity (IDIQ) contracts held by Axle Informatics LLC, Gap Solutions Inc., Kelly Services Inc., Guidehouse Digital LLC, and 22nd Century Technologies Inc. The primary objective is to ensure continuity of specialized scientific professional services across 29 NIH organizations, including the Office of the Director, 27 Institutes and Centers, and ARPA-H, while the agency finalizes a strategic procurement consolidation effort and a competitive follow-on acquisition. The proposed extension includes a basic ordering period from June 22, 2026, to June 21, 2027, with two optional six-month extensions extending through June 21, 2028. Additionally, the government seeks to revise FAR 52.216-22 to allow task orders to extend up to 36 months beyond the parent contract end date. While the combined maximum contract ordering value remains unchanged at $3,600,713,546, the estimated total dollar value for orders through the end of the extension is $2,174,615,674. The government projects the award of these modifications in April 2026. The SOAR program provides critical scientific staffing, such as bioinformatics scientists and molecular biologists, to support biomedical research and public health missions. The NIH has cited a critical need for these specific contract holders to avoid disruptions to ongoing research and patient diagnostics. Interested parties may submit capability statements and pricing information by March 5, 2027, although the government currently intends to proceed on a non-competitive basis with the existing holders.
Other Scientific and Technical Consulting Services

POSTED

9 months ago

DEADLINE

in 4 months
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS